Cardiol Therapeutics Inc. (NASDAQ:CRDL – Free Report) – Investment analysts at HC Wainwright lifted their Q3 2026 earnings per share (EPS) estimates for shares of Cardiol Therapeutics in a note issued to investors on Thursday, August 13th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of ($0.06) per share for the quarter, up from their previous forecast of ($0.08). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.24) EPS, FY2027 earnings at ($0.30) EPS, FY2028 earnings at $0.29 EPS, FY2029 earnings at $0.61 EPS and FY2030 earnings at $1.25 EPS.
Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.05.
Read Our Latest Report on CRDL
Cardiol Therapeutics Stock Performance
Shares of NASDAQ:CRDL opened at $1.80 on Monday. Cardiol Therapeutics has a 52 week low of $0.88 and a 52 week high of $1.94. The company’s 50 day moving average is $1.19 and its two-hundred day moving average is $1.19. The company has a market cap of $208.60 million, a PE ratio of -7.20 and a beta of 0.72.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in CRDL. Integrity Alliance LLC. acquired a new position in Cardiol Therapeutics during the fourth quarter worth approximately $416,000. Tejara Capital Ltd boosted its holdings in shares of Cardiol Therapeutics by 95.1% in the fourth quarter. Tejara Capital Ltd now owns 5,130,122 shares of the company’s stock valued at $4,893,000 after acquiring an additional 2,500,000 shares during the period. AdvisorShares Investments LLC boosted its holdings in shares of Cardiol Therapeutics by 7.3% in the fourth quarter. AdvisorShares Investments LLC now owns 597,977 shares of the company’s stock valued at $570,000 after acquiring an additional 40,589 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Cardiol Therapeutics in the first quarter valued at approximately $310,000. Finally, Simplex Trading LLC grew its position in shares of Cardiol Therapeutics by 96.9% during the fourth quarter. Simplex Trading LLC now owns 32,197 shares of the company’s stock worth $31,000 after acquiring an additional 15,842 shares during the last quarter. Hedge funds and other institutional investors own 12.49% of the company’s stock.
Cardiol Therapeutics Company Profile
Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.
CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.
Featured Articles
- Five stocks we like better than Cardiol Therapeutics
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
